Literature DB >> 3137246

Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital.

I Nachamkin1, P Axelrod, G H Talbot, S H Fischer, C B Wennersten, R C Moellering, R R MacGregor.   

Abstract

Enterococci isolated from different body sites were tested for high-level gentamicin resistance. A total of 259 enterococcal isolates were screened for resistance (MIC, greater than 2,000 micrograms/ml) by a broth-tube method. Thirty-nine (15.1%) were found to exhibit resistance and were confirmed by agar screening (1,000 micrograms/ml) and agar dilution MIC determinations. The majority of isolates also showed high-level resistance to kanamycin and streptomycin. The remaining isolates showed high-level resistance to gentamicin and kanamycin but not streptomycin. Synergy testing of several isolates confirmed the correlation between lack of synergy and high-level resistance. A retrospective clinical review was performed. Most patients had a source of definite or likely infection (79%). Serious infections such as endocarditis or meningitis were not observed during the course of this study. Retrospective clinical data suggest that in cases not involving endocarditis or meningitis, neither infection refractory to therapy nor relapse of infection is a common sequela of infection with gentamicin-resistant enterococci in hospitalized patients.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137246      PMCID: PMC266594          DOI: 10.1128/jcm.26.7.1287-1291.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  25 in total

1.  High-level resistance to gentamicin in Streptococcus faecalis: risk factors and evidence for exogenous acquisition of infection.

Authors:  M J Zervos; S Dembinski; T Mikesell; D R Schaberg
Journal:  J Infect Dis       Date:  1986-06       Impact factor: 5.226

2.  Antibiotic synergism--lessons from the enterococcus.

Authors:  R C Moellering
Journal:  Trans Am Clin Climatol Assoc       Date:  1983

3.  Enigmatic enterococcal endocarditis.

Authors:  W M Scheld; G L Mandell
Journal:  Ann Intern Med       Date:  1984-06       Impact factor: 25.391

4.  Optimal therapy for enterococcal endocarditis.

Authors:  J Herzstein; J L Ryan; R J Mangi; T P Greco; V T Andriole
Journal:  Am J Med       Date:  1984-02       Impact factor: 4.965

5.  Susceptibilities of enterococci to twelve antibiotics.

Authors:  R W Tofte; J A Solliday; K B Crossley
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

6.  Emergence of Streptococcus faecalis isolates with high-level resistance to multiple aminocyclitol aminoglycosides.

Authors:  D P Ikeda; A L Barry; S G Andersen
Journal:  Diagn Microbiol Infect Dis       Date:  1984-06       Impact factor: 2.803

7.  Enterococci from Bangkok, Thailand, with high-level resistance to currently available aminoglycosides.

Authors:  B E Murray; J Tsao; J Panida
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

8.  Transferable resistance and aminoglycoside-modifying enzymes in enterococci.

Authors:  H Y Chen; J D Williams
Journal:  J Med Microbiol       Date:  1985-10       Impact factor: 2.472

9.  Effects of medium and inoculum variations on screening for high-level aminoglycoside resistance in Enterococcus faecalis.

Authors:  D F Sahm; C Torres
Journal:  J Clin Microbiol       Date:  1988-02       Impact factor: 5.948

10.  Enterococcal infections in patients treated with moxalactam.

Authors:  R C Moellering
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec
View more
  21 in total

Review 1.  Screening and treatment of infections caused by resistant enterococci.

Authors:  D J Herman; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

2.  Species identification and antibiotic resistance patterns of the enterococci.

Authors:  E A Bryce; S J Zemcov; A M Clarke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-09       Impact factor: 3.267

3.  Factors influencing determination of high-level aminoglycoside resistance in Enterococcus faecalis.

Authors:  D F Sahm; S Boonlayangoor; P C Iwen; J L Baade; G L Woods
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

4.  Comparison of four methods for testing high-level aminoglycoside resistance in enterococci.

Authors:  P Yagupsky; S Petry; M A Menegus
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

5.  Evaluation of a commercial microtiter system (MicroScan) using both frozen and freeze-dried panels for detection of high-level aminoglycoside resistance in Enterococcus spp.

Authors:  S A Fuller; D E Low; A E Simor
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

Review 6.  The life and times of the Enterococcus.

Authors:  B E Murray
Journal:  Clin Microbiol Rev       Date:  1990-01       Impact factor: 26.132

7.  In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.

Authors:  R C Mercier; S R Penzak; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

8.  Bacteremia caused by hemolytic, high-level gentamicin-resistant Enterococcus faecalis.

Authors:  M M Huycke; C A Spiegel; M S Gilmore
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

9.  Detection of enterococcal high-level aminoglycoside resistance with MicroScan freeze-dried panels containing newly modified medium and Vitek Gram-Positive Susceptibility cards.

Authors:  D Weissmann; J Spargo; C Wennersten; M J Ferraro
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948

10.  Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit.

Authors:  M A Montecalvo; H Horowitz; C Gedris; C Carbonaro; F C Tenover; A Issah; P Cook; G P Wormser
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.